کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2828297 1162484 2006 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Iron chelation treatment with combined therapy with deferiprone and deferioxamine: A 12-month trial
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی زیست شناسی مولکولی
پیش نمایش صفحه اول مقاله
Iron chelation treatment with combined therapy with deferiprone and deferioxamine: A 12-month trial
چکیده انگلیسی
The simultaneous use of deferioxamine (DFO) and deferiprone (DFP) has an additive effect in iron excretion in transfusion-dependent thalassemic patients. In a prospective study, we evaluated the safety and effectiveness of combined therapy with these two chelators. Fifty patients with β-thalassemia were uniformly treated with DFP for 4 days per week and combined therapy with DFP and DFO for 3 days of the week. Efficacy was evaluated by ferritin and cardiac shortening fraction (SF). Hepatic hemosiderosis was also assessed by estimation of the T2 relaxation time by magnetic resonance in a subgroup of patients. Forty-three patients completed 1 year of therapy. Mean ferritin decreased from 3363.7 ± 2144.5 μg/L to 2323.2 ± 1740.8 μg/L (P < 0.0001). The reduction was significant even in the group of patients with ferritin <2500 μg/L. Significant improvement in T2 relaxation and SF was observed. The most common adverse events were gastrointestinal symptoms (20%) and transaminasemia (18%). The rate of agranulocytosis was 4.2 cases per 100 patient-years. Prolonged use of combined therapy with DFP and DFO is effective in decreasing iron load and improving cardiac function. Its possible association with higher incidence of agranulocytosis emphasizes the need for close monitoring.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Blood Cells, Molecules, and Diseases - Volume 36, Issue 1, January–February 2006, Pages 21-25
نویسندگان
, , , , , , , , , ,